April 13, 2021
In this video interview, Leyden Labs’ CEO Koenraad Wiedhaup sat down with GV General Partner and member of our board of directors, David Schenkein, M.D., to discuss the company becoming a part of GV’s life science portfolio and the completion of our €40 Million Series A financing. The two talk about the company’s plans for funding, including advancing our platform, developing our portfolio of products for respiratory viruses and building out our fantastic team. Other highlights include Leyden Labs’ birth story, insight into our proactive approach of targeting viral families and our intranasal products potential to give people the freedom to administer protection themselves.
Visit GV's news page to read the full article.